Eric Senneville1,2,3, Aurélien Dinh4,5, Tristan Ferry6,7, Eric Beltrand3,8, Nicolas Blondiaux3,9, Olivier Robineau1,2,3. 1. Infectious Diseases Department, Gustave Dron Hospital, 59200 Tourcoing, France. 2. Faculty of Medicine Henri Warembourg, Lille University, 59000 Lille, France. 3. French National Referent Centre for Complex Bone and Joint Infections, CRIOAC Lille-Tourcoing, 59000 Lille, France. 4. Infectious Diseases Department, Ambroise Paré Hospital, 92100 Boulogne-Billancourt, France. 5. French National Referent Centre for Complex Bone and Joint Infections, CRIOAC Paris-Ambroise, 75000 Paré, France. 6. Infectious Diseases Department, Croix-Rousse Hospital, 69004 Lyon, France. 7. French National Referent Centre for Complex Bone and Joint Infections, CRIOAC Lyon, 69004 Lyon, France. 8. Orthopaedic Surgery Department, G. Dron Hospital Tourcoing, 59200 Tourcoing, France. 9. Microbiology Laboratory, G. Dron Hospital Tourcoing, 59200 Tourcoing, France.
Abstract
OBJECTIVES: Data on clinical and biological tolerance of tedizolid (TZD) prolonged therapy are lacking. METHODS: We conducted a prospective multicentre study including patients with prosthetic joint infections (PJIs) who were treated for at least 6 weeks but not more than 12 weeks. RESULTS: Thirty-three adult patients of mean age 73.3 ± 10.5 years, with PJI including hip (n = 19), knee (n = 13) and shoulder (n = 1) were included. All patients were operated, with retention of the infected implants and one/two stage-replacements in 11 (33.3%) and 17/5 (51.5%/15.2%), respectively. Staphylococci and enterococci were the most prevalent bacteria identified. The mean duration of TZD therapy was 8.0 ± 3.27 weeks (6-12). TZD was associated with another antibiotic in 18 patients (54.5%), including rifampicin in 16 cases (48.5). Six patients (18.2%) had to stop TZD therapy prematurely because of intolerance which was potentially attributable to TZD (n = 2), early failure of PJI treatment (n = 2) or severe anaemia due to bleeding (n = 2). Regarding compliance with TZD therapy, no cases of two or more omissions of medication intake were recorded during the whole TZD treatment duration. CONCLUSIONS: These results suggest good compliance and a favourable safety profile of TZD, providing evidence of the potential benefit of the use of this agent for the antibiotic treatment of PJIs.
OBJECTIVES: Data on clinical and biological tolerance of tedizolid (TZD) prolonged therapy are lacking. METHODS: We conducted a prospective multicentre study including patients with prosthetic joint infections (PJIs) who were treated for at least 6 weeks but not more than 12 weeks. RESULTS: Thirty-three adult patients of mean age 73.3 ± 10.5 years, with PJI including hip (n = 19), knee (n = 13) and shoulder (n = 1) were included. All patients were operated, with retention of the infected implants and one/two stage-replacements in 11 (33.3%) and 17/5 (51.5%/15.2%), respectively. Staphylococci and enterococci were the most prevalent bacteria identified. The mean duration of TZD therapy was 8.0 ± 3.27 weeks (6-12). TZD was associated with another antibiotic in 18 patients (54.5%), including rifampicin in 16 cases (48.5). Six patients (18.2%) had to stop TZD therapy prematurely because of intolerance which was potentially attributable to TZD (n = 2), early failure of PJI treatment (n = 2) or severe anaemia due to bleeding (n = 2). Regarding compliance with TZD therapy, no cases of two or more omissions of medication intake were recorded during the whole TZD treatment duration. CONCLUSIONS: These results suggest good compliance and a favourable safety profile of TZD, providing evidence of the potential benefit of the use of this agent for the antibiotic treatment of PJIs.
Authors: L Khatchatourian; A Le Bourgeois; N Asseray; C Biron; M Lefebvre; D Navas; M Grégoire; B Gaborit; F Raffi; D Boutoille Journal: J Antimicrob Chemother Date: 2017-07-01 Impact factor: 5.790
Authors: Ruben Anemüller; Katherine Belden; Barry Brause; Mustafa Citak; Jose L Del Pozo; Lars Frommelt; Thorsten Gehrke; Angela Hewlett; Carlos A Higuera; Harriet Hughes; Michael Kheir; Kang-Il Kim; Sujith Konan; Christian Lausmann; Camelia Marculescu; Laura Morata; Isabel Ramirez; Markus Rossmann; Randi Silibovsky; Alex Soriano; Gina Ann Suh; Charles Vogely; Andrea Volpin; Jean Yombi; Akos Zahar; Werner Zimmerli Journal: J Arthroplasty Date: 2018-10-19 Impact factor: 4.757
Authors: Matteo Bassetti; Francesco Vitale; Giovanna Melica; Elda Righi; Antonio Di Biagio; Luigi Molfetta; Francesco Pipino; Mario Cruciani; Dante Bassetti Journal: J Antimicrob Chemother Date: 2005-02-10 Impact factor: 5.790
Authors: M Titécat; E Senneville; F Wallet; H Dezèque; H Migaud; R-J Courcol; C Loïez Journal: Orthop Traumatol Surg Res Date: 2013-08-27 Impact factor: 2.256
Authors: Taylor Morrisette; Kyle C Molina; Beatriz Da Silva; Scott W Mueller; Laura Damioli; Martin Krsak; Matthew A Miller; Douglas N Fish Journal: Open Forum Infect Dis Date: 2022-05-23 Impact factor: 4.423